Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Hangzhou Alltest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	896.27	920.38	1,318	1,982	2,179	285.64
Trading Asset Securities	1,652	1,657	1,471	1,833	780.2	415
Cash & Short-Term Investments	2,548	2,578	2,789	3,815	2,960	700.64
Cash Growth	-5.94%	-7.57%	-26.89%	28.90%	322.40%	459.38%
Accounts Receivable	142.52	125.12	100.87	138.66	208.2	163.44
Other Receivables	9.01	6.67	8.18	10.35	67.4	2.29
Receivables	151.53	131.79	109.05	149.02	275.6	165.72
Inventory	162	160.32	188.59	193.66	383.84	123.73
Prepaid Expenses	-	0.71	11.65	2.15	8.19	-
Other Current Assets	114.19	94.75	63.24	29.63	41.03	35.09
Total Current Assets	2,976	2,965	3,161	4,189	3,668	1,025
Property, Plant & Equipment	938.55	903.44	759.8	317.14	223.62	66.81
Long-Term Investments	79.35	128.67	22.95	12.2	54.32	-
Other Intangible Assets	103.78	104.97	110.43	93.03	28.12	28.79
Long-Term Deferred Tax Assets	23.12	22.2	30.18	46.44	3.82	4.07
Long-Term Deferred Charges	9.09	10.35	15.72	17.88	5.66	2.15
Other Long-Term Assets	75.42	51.1	15.53	18.96	24.62	24.11
Total Assets	4,205	4,186	4,116	4,695	4,008	1,151
Accounts Payable	68.18	104.8	77.61	171.17	360.65	62
Accrued Expenses	10.59	32.41	33.16	73.51	44.61	32.6
Current Portion of Leases	2.68	2.34	16.26	8.32	20.06	-
Current Income Taxes Payable	90.41	86.43	73.96	73.26	61.71	50.31
Current Unearned Revenue	48.78	40.84	41.62	147.2	226.27	33.38
Other Current Liabilities	33.66	32.37	31.56	37.29	0.91	0.15
Total Current Liabilities	254.3	299.19	274.16	510.75	714.2	178.45
Long-Term Leases	1.49	1.76	7.66	13.44	17.3	-
Long-Term Unearned Revenue	1.39	1.64	2.68	-	-	-
Long-Term Deferred Tax Liabilities	0.01	0.01	-	-	3.2	-
Total Liabilities	257.19	302.6	284.5	524.2	734.71	178.45
Common Stock	79.28	79.28	79.28	53.9	53.9	40.4
Additional Paid-In Capital	1,711	1,708	1,713	1,744	1,733	102.8
Retained Earnings	2,238	2,177	2,107	2,455	1,487	829.33
Treasury Stock	-113.01	-113.01	-103.4	-115.56	-	-
Comprehensive Income & Other	32.23	32.5	30.75	28.39	0.26	0.13
Total Common Equity	3,948	3,884	3,827	4,166	3,274	972.66
Minority Interest	-0.26	-0.22	4.31	4.4	-	-
Shareholders' Equity	3,948	3,883	3,832	4,171	3,274	972.66
Total Liabilities & Equity	4,205	4,186	4,116	4,695	4,008	1,151
Total Debt	4.16	4.1	23.91	21.77	37.36	-
Net Cash (Debt)	2,544	2,574	2,765	3,793	2,922	700.64
Net Cash Growth	-5.34%	-6.92%	-27.10%	29.80%	317.07%	459.38%
Net Cash Per Share	32.17	32.50	34.91	47.86	39.07	11.72
Filing Date Shares Outstanding	77.87	77.87	77.53	78.24	79.78	59.8
Total Common Shares Outstanding	77.87	77.87	78.16	78.24	79.78	59.8
Working Capital	2,721	2,666	2,887	3,678	2,954	846.73
Book Value Per Share	50.70	49.87	48.97	53.25	41.03	16.27
Tangible Book Value	3,844	3,779	3,717	4,073	3,246	943.87
Tangible Book Value Per Share	49.37	48.53	47.56	52.06	40.68	15.78
Buildings	-	403.78	194.44	198.85	58.13	46.61
Machinery	-	117.42	113.61	91.69	58.93	19.04
Construction In Progress	-	459.92	488.25	42.3	82.37	11.62

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.